Human immunodeficiency virus type 1 group M protease in Cameroon: Genetic diversity and protease inhibitor mutational features

Peter N. Fonjungo, Eitel N. Mpoudi, Judith N. Torimiro, George A. Alemnji, Laura T. Eno, Esther J. Lyonga, John N. Nkengasong, Renu B. Lal, Mark Rayfield, Marcia L. Kalish, Thomas M. Folks, Danuta Pieniazek

    Research output: Contribution to journalArticle

    45 Scopus citations

    Abstract

    To establish a baseline for monitoring resistance to protease inhibitors (PIs) and examining the efficacy of their use among persons in Cameroon infected with human immunodeficiency virus type 1 (HIV-1), we analyzed genetic variability and PI resistance-associated substitutions in PCR-amplified protease (PR) sequences in strains isolated from 110 HIV-1-infected, drug-naïve Cameroonians. Of the 110 strains, 85 were classified into six HIV-1 PR subtypes, A (n = 1), B (n = 1), F (n = 4), G (n = 7), H (n = 1), and J (n = 7), and a circulating recombinant form, CRF02-AG (n = 64). PR genes from the remaining 25 (23%) specimens were unclassifiable, whereas 2% (7 of 301) unclassifiable PR sequences were reported for a global collection. Two major PI resistance-associated mutations, 20M and 24I, were detected in strains from only two specimens, whereas secondary mutations were found in strains from all samples except one strain of subtype B and two strains of CRF02-AG. The secondary mutations showed the typical PI resistance-associated pattern for non-subtype B viruses in both classifiable and unclassifiable PR genes, with 36I being the predominant (99%) mutation, followed by 63P (18%), 20R (15%), 77I (13%), and 10I or 10V (11%). Of these mutations, dual and triple PI resistance-associated substitutions were found in 38% of all the Cameroonian strains. Compared with classifiable PR sequences, unclassifiable sequences had significantly more dual and triple substitutions (64% versus 30%; P = 0.004). Phenotypic and clinical evaluations are needed to estimate whether PI resistance during antiretroviral drug treatment occurs more rapidly in individuals infected with HIV-1 strains harboring multiple PI resistance-associated substitutions. This information may be important for determination of appropriate drug therapies for HIV-1-infected persons in Cameroon, where more than one-third of HIV-1 strains were found to carry dual and triple minor PI resistance-associated mutations.

    Original languageEnglish (US)
    Pages (from-to)837-845
    Number of pages9
    JournalJournal of clinical microbiology
    Volume40
    Issue number3
    DOIs
    StatePublished - Mar 20 2002

      Fingerprint

    ASJC Scopus subject areas

    • Microbiology (medical)

    Cite this

    Fonjungo, P. N., Mpoudi, E. N., Torimiro, J. N., Alemnji, G. A., Eno, L. T., Lyonga, E. J., Nkengasong, J. N., Lal, R. B., Rayfield, M., Kalish, M. L., Folks, T. M., & Pieniazek, D. (2002). Human immunodeficiency virus type 1 group M protease in Cameroon: Genetic diversity and protease inhibitor mutational features. Journal of clinical microbiology, 40(3), 837-845. https://doi.org/10.1128/JCM.40.3.837-845.2002